APA (7th ed.) Citation

O'Shaughnessy, E., Yasinskaya, Y., Dixon, C., Higgins, K., Moore, J., Reynolds, K., . . . Page, S. J. (2022). FDA Public Workshop Summary—Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs. Clinical Infectious Diseases, 74(11), 2061. https://doi.org/10.1093/cid/ciab904

Chicago Style (17th ed.) Citation

O'Shaughnessy, Elizabeth, et al. "FDA Public Workshop Summary—Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs." Clinical Infectious Diseases 74, no. 11 (2022): 2061. https://doi.org/10.1093/cid/ciab904.

MLA (9th ed.) Citation

O'Shaughnessy, Elizabeth, et al. "FDA Public Workshop Summary—Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs." Clinical Infectious Diseases, vol. 74, no. 11, 2022, p. 2061, https://doi.org/10.1093/cid/ciab904.